Effects of Abciximab as adjunctive therapy in primary percutaneous coronary intervention patients (results from the DANAMI‐2 trial)

References

• van't Hof A. W., Liem A., de Boer M. J., Zijlstra F. Clinical value of 12‐lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 1997; 350: 615–9
   PubMed Web of Science ®Google Scholar
• Claeys M. J., Bosmans J., Veenstra L., Jorens P., De R., Vrints C. J. Determinants and prognostic implications of persistent ST‐segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation 1999; 99: 1972–7
   PubMed Web of Science ®Google Scholar
• Ito H., Tomooka T., Sakai N., Yu H., Higashino Y., Fujii K., et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699–705
   PubMed Web of Science ®Google Scholar
• Somitsu Y., Nakamura M., Degawa T., Yamaguchi T. Prognostic value of slow resolution of ST‐segment elevation following successful direct percutaneous transluminal coronary angioplasty for recovery of left ventricular function. Am J Cardiol 1997; 80: 406–10
   PubMed Web of Science ®Google Scholar
• Antoniucci D., Rodriguez A., Hempel A., Valenti R., Migliorini A., Vigo F., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879–85
   PubMed Web of Science ®Google Scholar
• Antoniucci D., Migliorini A., Parodi G., Valenti R., Rodriguez A., Hempel A., et al. Abciximab‐supported infarct artery stent implantation for acute myocardial infarction and long‐term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004; 109: 1704–6
   PubMed Web of Science ®Google Scholar
• Brener S. J., Barr L. A., Burchenal J. E., Katz S., George B. S., Jones A. A., et al. Randomized, placebo‐controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734–41
   PubMed Web of Science ®Google Scholar
• Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–903
   PubMed Web of Science ®Google Scholar
• Neumann F. J., Kastrati A., Schmitt C., Blasini R., Hadamitzky M., Mehilli J., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915–21
   PubMed Web of Science ®Google Scholar
• Stone G. W., Grines C. L., Cox D. A., Garcia E., Tcheng J. E., Griffin J. J., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–66
   PubMed Web of Science ®Google Scholar
• Petronio A. S., Musumeci G., Limbruno U., De Carlo M., Baglini R., Paterni G., et al. Abciximab improves 6‐month clinical outcome after rescue coronary angioplasty. Am Heart J 2002; 143: 334–41
   PubMed Web of Science ®Google Scholar
• Bar F. W., Volders P. G., Hoppener P., Vermeer F., Meyer J., Wellens H. J. Development of ST‐segment elevation and Q‐ and R‐ wave changes in acute myocardial infarction and the influence of thrombolytic therapy. Am J Cardiol 1996; 77: 337–43
   PubMedGoogle Scholar
• Samson W. E., Scher A. M. Mechanism of S‐T segment alteration during acute myocardial injury. Circ Res 1960; 8: 780–7
   PubMed Web of Science ®Google Scholar
• Dissmann R., Goerke M., von Ameln H., Rennhak U., Schroeder J., Linderer T., et al. [Detection of early reperfusion and prediction of left ventricular damage from the course of increased ST values in acute myocardial infarct with thrombolysis]. Z Kardiol 1993; 82: 271–8
   PubMedGoogle Scholar
• Hlatky M. A., Califf R. M., Lee K. L., Pryor D. B., Wagner G. S., Rosati R. A. Prognostic significance of precordial ST‐segment depression during inferior acute myocardial infarction. Am J Cardiol 1985; 55: 325–9
   PubMed Web of Science ®Google Scholar
• Saran R. K., Been M., Furniss S. S., Hawkins T., Reid D. S. Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J 1990; 64: 113–7
   PubMedGoogle Scholar
• Schroder R., Dissmann R., Bruggemann T., Wegscheider K., Linderer T., Tebbe U., et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384–91
   PubMed Web of Science ®Google Scholar
• Andersen H. R., Nielsen T. T., Rasmussen K., Thuesen L., Kelbaek H., Thayssen P., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733–42
   PubMed Web of Science ®Google Scholar
• Andersen H. R., Nielsen T. T., Vesterlund T., Grande P., Abildgaard U., Thayssen P., et al. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction‐2 (DANAMI‐2). Am Heart J 2003; 146: 234–41
   PubMed Web of Science ®Google Scholar
• Hindman N. B., Schocken D. D., Widmann M., Anderson W. D., White R. D., Leggett S., et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. V. Specificity and method of application of the complete system. Am J Cardiol 1985; 55: 1485–90
   PubMed Web of Science ®Google Scholar
• Juergens C. P., Fernandes C., Hasche E. T., Meikle S., Bautovich G., Currie C. A., et al. Electrocardiographic measurement of infarct size after thrombolytic therapy. J Am Coll Cardiol 1996; 27: 617–24
   PubMed Web of Science ®Google Scholar
• Vejlstrup N., Clemmensen P., Steinmetz E., Krusell L. R., Hansen K. N., Christiansen I., et al. on behalf of the DANAMI‐2 investigators. Blinded end point adjudication in the Danish multicenter randomized stuy on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction (DANAMI‐2 trial). Heart Drug 2003; 3: 127–33
   Google Scholar
• de Lemos J. A., Antman E. M., Gibson C. M., McCabe C. H., Giugliano R. P., Murphy S. A., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST‐elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101: 239–43
   PubMed Web of Science ®Google Scholar
• Armstrong P. W., Wagner G., Goodman S. G., Van de W. F., Granger C., Wallentin L., et al. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J 2003; 24: 1515–22
   PubMedGoogle Scholar
• Gyongyosi M., Domanovits H., Benzer W., Haugk M., Heinisch B., Sodeck G., et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct‐related artery and improved myocardial tissue reperfusion – results of the Austrian multi‐centre randomized ReoPro‐BRIDGING Study. Eur Heart J 2004; 25: 2125–33
   PubMed Web of Science ®Google Scholar
• Thygesen K., Horder M., Nielsen B. L., Peterson P. H. Evolution of ST segment and Q and R waves during early phase of inferior myocardial infarction. Acta Med Scand 1979; 205: 25–30
   PubMedGoogle Scholar
• Thygesen K., Horder M., Petersen P. H., Nielsen B. L. Praecordial ECG mapping in acute anterior myocardial infarction. The evolution of ST segment and Q and R waves. Acta Med Scand 1981; 209: 161–7
   PubMedGoogle Scholar
• Eisenberg M. J., Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST‐segment elevation myocardial infarction. J Am Coll Cardiol 2003; 42: 1–6
   PubMed Web of Science ®Google Scholar
• Araújo J., Veloso H., Paiva J., Filho M., De Paola A. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: A meta‐analysis of randomized, controlled trials. Am Heart J 2005; 148: 937–43
   Google Scholar
• Kong D. F., Hasselblad V., Harrington R. A., White H. D., Tcheng J. E., Kandzari D. E., et al. Meta‐analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003; 92: 651–5
   PubMed Web of Science ®Google Scholar
• Topol E. J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905–14
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)‐3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT‐3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605–13
   PubMed Web of Science ®Google Scholar